Molecular Partners Ag (MOLN) Exchange Rate Effect (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Exchange Rate Effect of $77.9 for Q1 2026, up 183.38% year-over-year from $27.49 in Q1 2025, and up 100.0% quarter-over-quarter from -$1.7 million in Q4 2025.
Molecular Partners Ag (MOLN) Exchange Rate Effect (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Exchange Rate Effect for 7 consecutive years, with $77.9 the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 183.38% year-over-year to $77.9; the TTM figure through Mar 2026 stood at -$1.7 million (down 267.23% YoY), while the FY2025 annual figure was -$1.7 million, down 267.23% from the prior year.
- Exchange Rate Effect climbed to $77.9 in Q1 2026 per MOLN's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $1.0 million in Q4 2024 and bottomed at -$5.8 million in Q4 2023.
- Historically, Exchange Rate Effect has averaged -$363574.4 across 5 years, with a median of $1.21 in 2025.
- Annual changes were most pronounced in 2023 — Exchange Rate Effect plunged 2275.64% — and 2024, when it soared 4924.64%.
- Molecular Partners Ag's Exchange Rate Effect stood at $264328.1 in 2022, then plunged by 2275.64% to -$5.8 million in 2023, then jumped by 117.75% to $1.0 million in 2024, then slumped by 267.22% to -$1.7 million in 2025, then surged by 100.0% to $77.9 in 2026.
- Business Quant data shows MOLN's Exchange Rate Effect at $77.9 in Q1 2026, -$1.7 million in Q4 2025, and $3.75 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 77.90 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.90 |
| Mar 31, 2026 | 77.90 |
| Dec 31, 2025 | -1.71 Mn |
| Dec 31, 2025 | -1.71 Mn |
| Sep 30, 2025 | 3.75 |
| Sep 30, 2025 | 3.75 |
| Jun 30, 2025 | 1.21 |
| Jun 30, 2025 | 1.21 |
| Mar 31, 2025 | -93.43 |
| Mar 31, 2025 | -93.43 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | -6.93 |
| Sep 30, 2024 | -6.93 |
| Jun 30, 2024 | -5.53 |
| Jun 30, 2024 | -5.53 |
| Mar 31, 2024 | 886.76 |
| Mar 31, 2024 | 886.76 |
| Dec 31, 2023 | -5.75 Mn |
| Dec 31, 2023 | -5.75 Mn |